Patents by Inventor Robert E. Dempski

Robert E. Dempski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutant channelrhodopsin 2
    Patent number: 8748578
    Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: June 10, 2014
    Assignee: Max-Planck-Gesellschaft zur Foerderrung der Wissenschaften e.V.
    Inventors: Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
  • MUTANT CHANNELRHODOPSIN 2
    Publication number: 20130281379
    Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.
    Type: Application
    Filed: September 8, 2011
    Publication date: October 24, 2013
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaftern e.V.
    Inventors: Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4983400
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: January 8, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4900755
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: February 13, 1990
    Assignee: Merck & Co.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4832957
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
    Type: Grant
    Filed: July 25, 1988
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Methyldopa composition
    Patent number: 4404193
    Abstract: An aqueous suspension containing methyldopa and sucrose is disclosed. This composition is an oral dosage form for treating hypertension that is bioavailable.
    Type: Grant
    Filed: October 9, 1981
    Date of Patent: September 13, 1983
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Joseph L. O'Neill
  • Sustained release indomethacin
    Patent number: 4173626
    Abstract: A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated with a polymer to sustain the plasma level. The uncoated and coated pellets may be mixed with non-medicated pellets as a capsule filler.
    Type: Grant
    Filed: December 11, 1978
    Date of Patent: November 6, 1979
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Gunvant N. Mehta, Joseph C. Saboe